What Вивитрол Treats: Main Uses and Benefits

The primary role of this medication is to provide supportive pharmacological assistance for adults managing chronic substance use disorders. It is relevant for easing symptoms associated with alcohol dependence (AUD) and supporting the prevention of relapse to opioid dependence (OUD) following detoxification. Its core use is applied in addressing symptoms related to alcohol dependence and is relevant for easing challenging symptoms associated with the risk of relapse to opioid dependence after detoxification.

This medication is commonly used as an integrated part of a comprehensive management program that includes psychosocial support, supporting patients in managing symptoms that may become disruptive during their recovery efforts. A central benefit is its ability to help manage intense psychological and physiological cravings that often trigger relapse in both conditions. The medication assists with managing symptom clusters related to the consumption of alcohol and opioids, including those linked to the rewarding aspects of use, and contributes to easing the overall symptom load.

The overarching patient benefit is its contribution to managing symptoms linked to relapse, which helps maintain a sense of stability when symptoms are more noticeable. This supportive therapy assists patients in coping more steadily with the challenges of recovery by easing distress related to potential relapse.

Quick Fact: Relief for Intense Cravings

The medication is commonly used to help with persistent cravings for both alcohol and opioids, which often create noticeable physiological strain and interfere with daily comfort.

Eligibility Profile: Who Can and Cannot Use Vivitrol

Official regulatory documents establish strict patient eligibility criteria based on health status and certain comorbidities. The medicine is indicated for use only in adults (age 18 and older) managing alcohol dependence or preventing relapse to opioid dependence following detoxification.

Contraindicated Populations

Vivitrol is strictly contraindicated and must not be used in the following populations:

• Patients currently receiving opioid analgesics or those with current physiologic opioid dependence.
• Individuals in a state of acute opioid withdrawal.
• Patients who have failed the naloxone challenge test or have a positive urine screen for opioids.
• Patients with a history of acute hepatitis or liver failure.
• Individuals with a known hypersensitivity to naltrexone or any component of the formulation.

Conditional and Restricted Use

Use requires specific conditions to be met or is restricted in certain groups:

• Opioid-Free Status: Patients must be opioid-free for a minimum of 7 to 14 days prior to the first injection to prevent precipitated withdrawal.
• Age Limitations: Safety and efficacy have not been established in pediatric patients (under 18 years).
• Organ Impairment: Caution is recommended in administering the drug to patients with moderate to severe renal impairment. Pharmacokinetics have not been evaluated in severe hepatic impairment.
• Pregnancy/Lactation: Use during pregnancy is permitted only if the potential benefit justifies the potential risk. Use while breastfeeding is not recommended as naltrexone is excreted in human milk.

The official interaction profile for Vivitrol is defined primarily by its role as an opioid antagonist, leading to strict regulatory constraints.

Co-administration with opioid analgesics and other opioid-containing medicines, including specific cough and cold or antidiarrheal preparations, is formally contraindicated by regulatory agencies. This restriction is based on the risk of immediate antagonism of the opioid's effect and the potential to precipitate severe withdrawal. Use is also prohibited in any patient with current physiologic opioid dependence or those in acute withdrawal.

A procedural constraint mandates a minimum of 7 to 14 days of opioid abstinence prior to the first injection to mitigate the risk of severe precipitated withdrawal.

Pharmacokinetically, naltrexone metabolism is documented as not involving the CYP P450 enzyme system. However, official sources note interactions related to other pathways. Certain drugs, such as UGT inducers (e.g., apalutamide, mitapivat), may officially decrease naltrexone systemic exposure. Conversely, the co-administration of Vivitrol formally results in increased plasma levels of acamprosate.

The regulatory documentation confirms Vivitrol does not cause a disulfiram-like reaction with ethanol. For specific populations, caution is warranted in individuals with moderate to severe renal impairment due to the drug's primary excretion route. Pharmacokinetic data have not been evaluated for severe hepatic impairment, and the product is prohibited in acute liver failure.

The Core Mechanism: Opioid Receptor Blockade

VIVITROL's active ingredient, naltrexone, is an opioid receptor antagonist administered as a long-acting injectable formulation. Its primary action is to bind tightly to and occupy the mu-opioid receptors in the central nervous system. This action blocks both external opioids and the body's natural opioids (endorphins) from attaching, which fundamentally alters signaling within the associated neural pathways.

Modulating the Central Reward Pathway

The blockade of mu-opioid receptors acts within the mesolimbic pathway, the brain's main reward system. By occupying these critical binding sites, the mechanism suppresses signaling sequences that lead to the release of reward-related neurotransmitters. This targeted pathway interference limits the impact of excessive mediator activity and results in the modulation of overactive physiological responses linked to reinforcement.

Competitive Action and Sustained Blockade

Naltrexone exerts its effect through a competitive mechanism, meaning it out-competes other substances for receptor access. This action engages mechanisms that influence regulatory feedback within these pathways, leading to a sustained physiological adjustment. The mechanism maintains a modulated state within the targeted pathways by sustaining the receptor blockade over an extended period.

Official Administration Guidelines for VIVITROL (Naltrexone Extended-Release)

VIVITROL is an extended-release injectable medication requiring strict adherence to established administration guidelines.

Dosing and Administration Protocol

The medicine is administered as a single 380 mg dose of naltrexone extended-release injectable suspension. It is intended for administration only by a healthcare provider. Self-administration is not permitted.

• Route: The medicine must be administered as a deep intramuscular (IM) injection exclusively into the gluteal muscle (buttock). It is prohibited to administer VIVITROL intravenously (IV) or subcutaneously (SC).
• Frequency: The standard dosing schedule is once every four weeks or once a month. If a dose is missed, it should be received as soon as possible.
• Pre-treatment Requirement: Before the first dose is administered, the patient must be opioid-free for a minimum period of 7 to 10 days to avoid precipitation of acute withdrawal syndrome.

Procedural Requirements

The medication arrives in a kit that requires in-clinic preparation:

1. The powder (microspheres) and diluent must be brought to room temperature.
2. The suspension must be reconstituted immediately prior to administration using only the provided components.
3. The healthcare provider must alternate the injection site between the left and right gluteal muscles for subsequent monthly injections. Proper needle size (1.5 or 2 inches) is selected based on the patient's body habitus to ensure the injection is deep intramuscular.

These guidelines collectively define the standardized, professional-administered use of VIVITROL.

Research Evidence / Overview of Studies for Вивитрол

Evidence for Use in Alcohol Use Disorder (AUD)

Research for adults dealing with alcohol dependence was studied for how symptoms change over time, primarily in randomized controlled trials (RCTs). These short-term studies monitored outcomes related to alcohol consumption, such as the frequency of heavy drinking days and rates of abstinence, comparing the active injection plus counseling to placebo plus counseling. Findings described patterns where measurements for heavy drinking days were lower in the active group, particularly in the subgroup of patients who achieved continuous abstinence for at least seven days before the first injection. Data are still emerging for patients who were actively drinking when research began, as less clear patterns were described in this group.

Evidence for Use in Opioid Use Disorder (OUD)

Evidence for the prevention of relapse to opioid dependence comes from RCTs applied to adult patients who had completed opioid detoxification (confirmed opioid-free for 7–14 days). Trials monitored primary outcomes such as confirmed opioid abstinence (verified by drug screens) and the time until a first relapse event. Studies reported that the injection group data show patterns related to maintaining abstinence when observed alongside the placebo group. The strict requirement for prior detoxification means the results apply only to this specific studied population, and data for patients in active use are insufficient.

Long-Term Evidence and Research Limitations

The primary trials typically monitored outcomes for six months, which is the defined time interval for which the most structured evidence is available. While extension studies contribute to the broader evidence landscape, long-term effects are not fully established, and the durability of the measured effect may diminish after the final dose. Comparative evidence is lacking regarding whether research examined this extended-release medication directly against other standard-of-care treatments for OUD. Furthermore, data for certain groups remain insufficient, such as pregnant patients, children, and older adults, as they were generally excluded from the main randomized trials.

Key Studies & References

1. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders (Lee et al., 2016)

Common questions about Вивитрол (FAQ)

Q: Does this medicine make you sleepy?

Official regulatory documents indicate that sleepiness (somnolence) and dizziness are common side effects of this medicine. Because somnolence and dizziness are known side effects, regulatory information advises caution regarding the operation of machinery or driving until a person knows how the medicine affects them.

Q: Can children 2 years old use it?

The approved indications for this product generally apply to adults 18 years of age and older. While certain regulatory documents may include use for some specific conditions in children, such as partial-onset seizures, the specific age ranges for any use are highly dependent on the condition and country. The use of this medication in children, regardless of age, should be discussed with and determined by a healthcare provider.

Q: Is it safe long-term?

Regulatory warnings for this medicine address safety considerations for ongoing use, including information about the potential risk of suicidal thoughts or behavior. Official documents also note the risk of withdrawal symptoms if the medicine is stopped abruptly, which is a key safety point for long-term treatment. Safety information is based on the specific conditions and patient populations studied.

How to Store and Dispose of Vivitrol

Official regulatory guidelines strictly define the storage and handling requirements for the Vivitrol extended-release injectable suspension. The entire dose pack must be stored under refrigeration, maintained at a temperature between 2 C and 8 C (36 F to 46 F).

Mandatory Storage Rules:

• The product must not be frozen.
• If stored outside of refrigeration, the temperature must not exceed 25 C (77 F), and this period must be limited to no more than 7 days prior to use.
• Before preparation, the carton must be allowed to reach room temperature for approximately 45 minutes.

Disposal Requirements:

Per official instructions, all used or damaged administration needles from the dose pack must be immediately disposed of in a designated, puncture-proof sharps container.